Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Clinical trial NCT02259621 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02259621
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2022-10-14
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.